Eyepoint Pharmaceuticals Inc
EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib… Read more
Eyepoint Pharmaceuticals Inc (EYPT) - Total Liabilities
Latest total liabilities as of September 2025: $51.51 Million USD
Based on the latest financial reports, Eyepoint Pharmaceuticals Inc (EYPT) has total liabilities worth $51.51 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Eyepoint Pharmaceuticals Inc - Total Liabilities Trend (2000–2024)
This chart illustrates how Eyepoint Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Eyepoint Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Eyepoint Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Brookfield Wealth Solutions Ltd.
NYSE:BNT
|
USA | $135.91 Billion |
|
Com7 Public Company Limited
BK:COM7-R
|
Thailand | ฿16.52 Billion |
|
Rent-A-Center Inc
F:RAC
|
Germany | €2.52 Billion |
|
Xintec
TWO:3374
|
Taiwan | NT$5.45 Billion |
|
Nippon Gas Co., Ltd.
PINK:NPNGY
|
USA | $74.23 Billion |
|
Rianlon Corp
SHE:300596
|
China | CN¥5.05 Billion |
|
Jiangsu Flowers King
SHG:603007
|
China | CN¥1.34 Billion |
Liability Composition Analysis (2000–2024)
This chart breaks down Eyepoint Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.18 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.26 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.20 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Eyepoint Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Eyepoint Pharmaceuticals Inc (2000–2024)
The table below shows the annual total liabilities of Eyepoint Pharmaceuticals Inc from 2000 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $81.96 Million | -7.76% |
| 2023-12-31 | $88.86 Million | +5.80% |
| 2022-12-31 | $83.99 Million | +6.32% |
| 2021-12-31 | $78.99 Million | +7.95% |
| 2020-12-31 | $73.18 Million | +13.20% |
| 2019-12-31 | $64.64 Million | +7.77% |
| 2018-12-31 | $59.98 Million | +1023.07% |
| 2017-12-31 | $5.34 Million | -50.26% |
| 2016-12-31 | $10.74 Million | +19.32% |
| 2015-12-31 | $9.00 Million | +16.16% |
| 2014-12-31 | $7.75 Million | -9.38% |
| 2013-12-31 | $8.55 Million | +22.81% |
| 2012-12-31 | $6.96 Million | -28.09% |
| 2011-12-31 | $9.68 Million | -2.94% |
| 2010-12-31 | $9.97 Million | -26.47% |
| 2009-12-31 | $13.56 Million | -22.23% |
| 2008-12-31 | $17.44 Million | -13.71% |
| 2007-12-31 | $20.21 Million | -35.63% |
| 2006-12-31 | $31.40 Million | +1919.22% |
| 2005-12-31 | $1.56 Million | 0.00% |
| 2004-12-31 | $1.56 Million | +15.46% |
| 2003-12-31 | $1.35 Million | +128.90% |
| 2002-12-31 | $588.38K | +303.71% |
| 2000-12-31 | $145.74K | -- |